Aprea Therapeutics shareholders elect three Class I directors at annual meeting

• Aprea Therapeutics held its annual shareholder meeting on June 16, 2026.
• Investors approved a charter amendment authorizing the board to carry out a reverse stock split.
• If implemented, the reverse split ratio can range from 1-for-3 to 1-for-8, with any fractional shares rounded up.
• Shareholders ratified EisnerAmper as the independent registered public accounting firm for the 2026 fiscal year.
• Shareholders selected a non-binding advisory vote to hold future say-on-pay votes every year.
• An adjournment proposal was adopted to allow more time to solicit votes if needed to secure support for the reverse stock split.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprea Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-075151), on June 17, 2026, and is solely responsible for the information contained therein.